A Pilot Study to Evaluate the Clinical and Biological Tolerance of Sitagliptin With Pegylated Interferon alfa2a Plus Ribavirin Combination Therapy in Chronic Hepatitis C Patients
Phase of Trial: Phase I
Latest Information Update: 15 Jul 2014
At a glance
- Drugs Sitagliptin (Primary) ; Peginterferon alfa-2a; Ribavirin
- Indications Hepatitis C
- Focus Adverse reactions
- 10 Jun 2017 Biomarkers information updated
- 17 Jan 2014 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 14 May 2013 Planned end date changed from 1 Dec 2014 to 1 Dec 2015 as reported by ClinicalTrials.gov.